Advertisement

PharmacoEconomics & Outcomes News

, Volume 817, Issue 1, pp 13–14 | Cite as

Cost-effective options for advanced renal cell carcinoma

Meeting report
  • 3 Downloads

First-line nivolumab + ipilimumab

Combination treatment with nivolumab and ipilimumab appears to be cost effective compared with sunitinib as first-line treatment in patients with advanced or metastatic RCC, according to a poster presentation by authors from Pharmerit International and Bristol-Myers Squibb.1

A partitioned survival model populated with data from the multinational CheckMate 214 study and the Netherlands PERCEPTION Registry was used to evaluate the cost effectiveness of nivolumab plus ipilimumab versus sunitinib in intermediate- to poor-risk patients with advanced RCC, from a Netherlands societal perspective over a 30-year time horizon.

Nivolumab + ipilimumab was estimated to achieve an incremental gain of 1.4 QALYs compared with sunitinib at a higher total cost (€312 073 [2017 euros] vs €236 550), resulting in an incremental cost-effectiveness ratio (ICER) of €55 170 per QALY gained. In scenario analyses, the net benefit of nivolumab plus ipilimumab was higher in most...

References

  1. 1.
    Klijn S, et al. Cost-Effectiveness of Nivolumab + Ipilimumab in First-Line Treatment of Advanced or Metastatic Renal Cell Carcinoma in the Netherlands. 21st Annual European Congress of the International Society for Pharmacoeconomics and Outcomes Research : (plus poster) abstr. PCN190, 10 Nov 2018. Available from: URL: https://tools.ispor.org/ScientificPresentationsDatabase/Presentation/87945?pdfid=58449
  2. 2.
    Lakhdari K, et al. A Cost-Effectiveness Analysis of Nivolumab in Combination with Ipilimumab for the Treatment of Advanced Renal Cell Carcinoma in Canada. 21st Annual European Congress of the International Society for Pharmacoeconomics and Outcomes Research : (plus poster) abstr. PCN136, 10 Nov 2018. Available from: URL: https://tools.ispor.org/ScientificPresentationsDatabase/Presentation/85488?pdfid=58687
  3. 3.
    Skentzou E, et al. Cost-Effectiveness of Cabozantinib Versus Sunitinib or Pazopanib as First-Line Treatment of Patients with Advanced Renal Cell Carcinoma in the UK. 21st Annual European Congress of the International Society for Pharmacoeconomics and Outcomes Research : abstr. PCN94, 10 Nov 2018. Available from: URL: https://tools.ispor.org/ScientificPresentationsDatabase/Presentation/85429?pdfid=58691
  4. 4.
    Kim S, et al. Cost-Effectiveness of Cabozantinib for Patients with Advanced Renal Cell Carcinoma after Failure of Prior Therapy in South Korea. 21st Annual European Congress of the International Society for Pharmacoeconomics and Outcomes Research : abstr. PCN144, 10 Nov 2018. Available from: URL: https://tools.ispor.org/ScientificPresentationsDatabase/Presentation/85389?pdfid=58689
  5. 5.
    Mac Mullen M. Assessing the Budget Impact of Including Sunitinib for the Treatment of Metastatic Renal Cell Carcinoma in Argentina. 21st Annual European Congress of the International Society for Pharmacoeconomics and Outcomes Research : abstr. PCN70, 10 Nov 2018. Available from: URL: https://tools.ispor.org/ScientificPresentationsDatabase/Presentation/85506?pdfid=58681
  6. 6.
    Derkach EV, et al. The Evaluation of the Economic Efficiency of Lenvatinib in Combination with Everolimus in Russian Patients with Disseminated Renal Cell Carcinoma. 21st Annual European Congress of the International Society for Pharmacoeconomics and Outcomes Research : abstr. PCN92, 10 Nov 2018. Available from: URL: https://tools.ispor.org/ScientificPresentationsDatabase/Presentation/87927?pdfid=58454
  7. 7.
    McDonald L, et al. Understanding Patient Perspectives of Renal Cell Carcinoma Using Social Media: a Qualitative Analysis. 21st Annual European Congress of the International Society for Pharmacoeconomics and Outcomes Research : (plus poster) abstr. PCN373, 10 Nov 2018. Available from: URL: https://tools.ispor.org/ScientificPresentationsDatabase/Presentation/86456?pdfid=58612

Copyright information

© Springer Nature Switzerland AG 2018

Personalised recommendations